Bio-Rad Laboratories (BIO) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $364.82, +0.66% vs the prior close of $362.43.
- Volume 247.80K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BIO rises 0.7% to $364.82. Closed at $364.82, +0.66% vs the prior close of $362.43. Day range $359.88–$368.54, opened at $364.90.
BIO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — BIO rises 0.7% to $364.82
- Closed at $364.82, +0.66% vs the prior close of $362.43. Day range $359.88–$368.54, opened at $364.90.
- Volume was 247.80K shares, 1.0x its 50-day average of 260.28K.
- Price is -2.1% vs its 50-day average ($372.48) and +17.5% vs its 200-day average ($310.62).
- 52-week range $236.73–$396.23; today's close sits at 80% of that range, 7.9% below the 52-week high.
Oct 14, 2026 — BIO dips 0.4% to $362.43, 3 down days in a row
- Closed at $362.43, -0.36% vs the prior close of $363.73. Day range $361.27–$371.07, opened at $367.86.
- Volume was 297.40K shares, 1.1x its 50-day average of 259.82K.
- Price is -2.6% vs its 50-day average ($372.14) and +16.8% vs its 200-day average ($310.31).
- 52-week range $236.73–$396.23; today's close sits at 79% of that range, 8.5% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — BIO ends flat (-0.2%) to $363.73
- Closed at $363.73, -0.19% vs the prior close of $364.42. Day range $358.43–$369.43, opened at $369.00.
- Volume was 132.60K shares, 0.5x its 50-day average of 263.08K — lighter than usual.
- Price is -2.1% vs its 50-day average ($371.55) and +17.3% vs its 200-day average ($310.02).
- 52-week range $236.73–$396.23; today's close sits at 80% of that range, 8.2% below the 52-week high.
Oct 12, 2026 — BIO dips 0.5% to $364.42
- Closed at $364.42, -0.48% vs the prior close of $366.16. Day range $359.41–$369.85, opened at $369.85.
- Volume was 181.10K shares, 0.7x its 50-day average of 263.26K.
- Price is -1.8% vs its 50-day average ($370.97) and +17.7% vs its 200-day average ($309.71).
- 52-week range $236.73–$396.23; today's close sits at 80% of that range, 8.0% below the 52-week high.
Oct 9, 2026 — BIO rises 1.6% to $366.16
- Closed at $366.16, +1.60% vs the prior close of $360.40. Day range $361.32–$368.67, opened at $364.32.
- Volume was 139.00K shares, 0.5x its 50-day average of 264.38K — lighter than usual.
- Price is -1.1% vs its 50-day average ($370.19) and +18.3% vs its 200-day average ($309.39).
- 52-week range $236.73–$396.23; today's close sits at 81% of that range, 7.6% below the 52-week high.
Oct 8, 2026 — BIO dips 2.0% to $360.40, 3 down days in a row
- Closed at $360.40, -2.04% vs the prior close of $367.92. Day range $353.97–$372.59, opened at $371.99.
- Volume was 312.00K shares, 1.2x its 50-day average of 265.37K.
- Price is -2.4% vs its 50-day average ($369.40) and +16.6% vs its 200-day average ($309.08).
- 52-week range $236.73–$396.23; today's close sits at 78% of that range, 9.0% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — BIO ends flat (-0.2%) to $367.92
- Closed at $367.92, -0.25% vs the prior close of $368.83. Day range $363.98–$374.60, opened at $373.16.
- Volume was 251.90K shares, 0.9x its 50-day average of 272.18K.
- Price is -0.2% vs its 50-day average ($368.74) and +19.1% vs its 200-day average ($308.79).
- 52-week range $236.73–$396.23; today's close sits at 82% of that range, 7.1% below the 52-week high.
Oct 6, 2026 — BIO dips 2.9% to $368.83
- Closed at $368.83, -2.89% vs the prior close of $379.82. Day range $367.49–$390.00, opened at $383.38.
- Volume was 162.20K shares, 0.6x its 50-day average of 275.91K — lighter than usual.
- Price is +0.2% vs its 50-day average ($368.00) and +19.6% vs its 200-day average ($308.45).
- 52-week range $236.73–$396.23; today's close sits at 83% of that range, 6.9% below the 52-week high.
Oct 5, 2026 — BIO rises 2.9% to $379.82
- Closed at $379.82, +2.89% vs the prior close of $369.14. Day range $363.96–$381.78, opened at $368.07.
- Volume was 279.40K shares, 1.0x its 50-day average of 277.44K.
- Price is +3.5% vs its 50-day average ($366.95) and +23.3% vs its 200-day average ($308.11).
- 52-week range $236.73–$396.23; today's close sits at 90% of that range, 4.1% below the 52-week high.
Oct 2, 2026 — BIO jumps 3.8% to $369.14
- Closed at $369.14, +3.82% vs the prior close of $355.57. Day range $357.28–$369.40, opened at $357.28.
- Volume was 223.60K shares, 0.8x its 50-day average of 280.02K.
- Price is +1.0% vs its 50-day average ($365.64) and +20.0% vs its 200-day average ($307.72).
- 52-week range $236.73–$396.23; today's close sits at 83% of that range, 6.8% below the 52-week high.
BIO latest news & SEC filings
Every SEC filing by or about BIO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 9, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 9, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 9, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 9, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 9, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 9, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 4, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $651.00M (prior year $651.60M) (-0.1% vs Jun 30, 2025)
- Net income: $371.40M (prior year $317.80M) (+16.9% vs Jun 30, 2025)
- Diluted EPS: $13.85 (prior year $11.67) (+18.7% vs Jun 30, 2025)
Aug 4, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 2.05 — Costs tied to exiting activities / restructuring.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade BIO
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: Apr 30, 2026, Feb 12, 2026, Oct 29, 2025. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.47% (largest 5.9%).
- Liquidity: about 253.50K shares (≈$92.48M) trade per day on average.
- 52-week position: $364.82 vs a range of $236.73–$396.23 (80% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 2 sales; latest: Eva Anette Engelhardt sold 550 shares on May 11, 2026.
- Latest filings: 10-Q Aug 4, 2026; 8-K Aug 4, 2026; 10-Q Apr 30, 2026.
- Listing: NYSE · industry: Laboratory Analytical Instruments.
BIO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 364.90 | 368.54 | 359.88 | 364.82 | 247.80K |
| Oct 14, 2026 | 367.86 | 371.07 | 361.27 | 362.43 | 297.40K |
| Oct 13, 2026 | 369.00 | 369.43 | 358.43 | 363.73 | 132.60K |
| Oct 12, 2026 | 369.85 | 369.85 | 359.41 | 364.42 | 181.10K |
| Oct 9, 2026 | 364.32 | 368.67 | 361.32 | 366.16 | 139.00K |
| Oct 8, 2026 | 371.99 | 372.59 | 353.97 | 360.40 | 312.00K |
| Oct 7, 2026 | 373.16 | 374.60 | 363.98 | 367.92 | 251.90K |
| Oct 6, 2026 | 383.38 | 390.00 | 367.49 | 368.83 | 162.20K |
| Oct 5, 2026 | 368.07 | 381.78 | 363.96 | 379.82 | 279.40K |
| Oct 2, 2026 | 357.28 | 369.40 | 357.28 | 369.14 | 223.60K |
| Oct 1, 2026 | 373.87 | 379.67 | 353.30 | 355.57 | 264.60K |
| Sep 30, 2026 | 377.61 | 380.88 | 374.02 | 377.71 | 228.60K |
| Sep 29, 2026 | 377.73 | 381.56 | 374.79 | 379.55 | 261.70K |
| Sep 28, 2026 | 376.98 | 383.95 | 373.18 | 377.69 | 272.60K |
| Sep 25, 2026 | 384.14 | 387.00 | 376.43 | 381.00 | 253.60K |
| Sep 24, 2026 | 377.73 | 389.38 | 376.18 | 387.54 | 374.20K |
| Sep 23, 2026 | 379.27 | 382.85 | 374.77 | 378.88 | 177.20K |
| Sep 22, 2026 | 377.53 | 383.25 | 374.01 | 379.57 | 374.70K |
| Sep 21, 2026 | 381.58 | 381.58 | 373.47 | 377.33 | 311.50K |
| Sep 18, 2026 | 383.05 | 383.05 | 374.81 | 376.41 | 324.30K |
About Bio-Rad Laboratories
Bio-Rad Laboratories (BIO) is listed on the NYSE and classified by the SEC under “Laboratory Analytical Instruments”. Its business address is in HERCULES, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 12208.
BIO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Schwartz Allison | Director | Sep 9, 2026 |
| Jeffrey L Edwards | Director | Apr 23, 2026 |
| Greg K Hinckley | Director | Apr 23, 2026 |
| Melinda Litherland Pei | Director | Apr 23, 2026 |
| Arnold A Pinkston | Director | Apr 23, 2026 |
| Norman D Schwartz | Chairman & CEO | Sep 9, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| James Barry | EVP, President, LSG | Sep 9, 2026 |
| Jonathan P. Divincenzo | President & COO | Sep 9, 2026 |
| Eva Anette Engelhardt | EVP, President, CDG | Sep 9, 2026 |
| Courtney C Enloe | EVP, General Counsel & Sec | Sep 9, 2026 |
| Sedat Evran | EVP, Global Supply Chain | Sep 9, 2026 |
| Roop Kalyan Lakkaraju | EVP, Chief Financial Officer | Sep 9, 2026 |
| Rajat Mehta | EVP, GBL Commercial Operations | Sep 9, 2026 |
| Norman D Schwartz | Chairman & CEO | Sep 9, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 11, 2026 | Eva Anette Engelhardt | Sale | 550 | $246.54 |
| Nov 6, 2025 | James Barry | Sale | 700 | $306.18 |
BIO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $2.58B | $759.90M | 27.85 | $532.20M |
| Dec 31, 2024 | $2.57B | $-1.84B | -65.36 | $455.20M |
| Dec 31, 2023 | $2.67B | $-637.30M | -21.82 | $374.90M |
| Dec 31, 2022 | $2.80B | $-3.63B | -121.79 | $194.40M |
| Dec 31, 2021 | $2.92B | $4.25B | 140.83 | $669.46M |
Latest balance sheet: total assets $10.25B, total liabilities $3.08B, cash $517.00M (as of Jun 30, 2026).
BIO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $332.88 |
| Apr 30, 2026 | 8-K Item 2.02 (results) | $280.12 |
| Feb 12, 2026 | 8-K Item 2.02 (results) | $292.42 |
| Oct 29, 2025 | 8-K Item 2.02 (results) | $319.47 |
| Jul 31, 2025 | 8-K Item 2.02 (results) | $241.95 |
| May 1, 2025 | 8-K Item 2.02 (results) | $240.43 |
| Feb 13, 2025 | 8-K Item 2.02 (results) | $306.36 |
| Oct 30, 2024 | 8-K Item 2.02 (results) | $330.58 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Feb 15, 2024 | 8-K Item 2.02 (results) | — |
| Oct 26, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Laboratory Analytical Instruments
Illumina (ILMN)Waters (WAT)Mettler Toledo International Inc/ (MTD)Revvity (RVTY)Agilent Technologies (A)10x Genomics (TXG)Bruker (BRKR)Avantor (AVTR)Alamar Biosciences (ALMR)Pacific Biosciences Of California (PACB)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on BIO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.